博雅生物(300294) - 2021 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2021 was ¥672,101,665.87, representing a 3.29% increase compared to ¥650,690,995.81 in the same period last year[8]. - The net profit attributable to shareholders for Q1 2021 was ¥100,736,164.66, up 5.04% from ¥95,900,464.56 year-on-year[8]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥98,876,255.69, reflecting a 12.38% increase from ¥87,981,685.60 in the previous year[8]. - The basic earnings per share for Q1 2021 were ¥0.24, up 4.35% from ¥0.23 in the same period last year[8]. - The diluted earnings per share for Q1 2021 were also ¥0.24, reflecting a 4.35% increase compared to ¥0.23 year-on-year[8]. - Operating profit reached ¥122,974,479.86, reflecting a growth of 5.96% compared to the same period last year[28]. - Net profit for the current period was ¥103,957,040.08, compared to ¥99,887,304.66 in the previous period, representing a growth of approximately 4.1%[78]. - The company reported investment income of ¥7,801,292.65, compared to a loss of ¥350,982.18 in the previous period, indicating a significant turnaround[74]. Cash Flow and Liquidity - The net cash flow from operating activities for Q1 2021 was ¥159,306,575.70, a significant increase of 127.42% compared to ¥70,048,130.64 in the same period last year[8]. - Cash flow from operating activities totaled ¥638,313,730.36, slightly down from ¥657,032,658.71 in the previous period[85]. - Cash and cash equivalents at the end of the period were ¥658,990,471.10, compared to ¥654,858,424.20 at the end of the previous period[90]. - The company’s cash inflow from operating activities was primarily driven by an increase in cash received from sales, which totaled 296,802,996.48 CNY, slightly up from 296,135,799.59 CNY[92]. - Cash outflow from operating activities decreased to 598,739,636.59 CNY from 632,748,694.47 CNY, a decline of 5.4%[92]. - Cash and cash equivalents decreased from ¥645,846,795.60 to ¥386,343,704.73, a drop of about 40%[63]. Assets and Liabilities - The total assets at the end of the reporting period were ¥5,005,101,156.91, down 2.97% from ¥5,158,535,284.56 at the end of the previous year[8]. - Total liabilities decreased from ¥966,078,096.11 to ¥708,746,713.24, a decline of approximately 26.6%[62]. - Current liabilities decreased from ¥871,927,797.99 to ¥662,698,410.19, a reduction of about 24%[59]. - Long-term equity investments decreased from ¥1,607,577,029.36 to ¥1,508,395,766.87, a decline of approximately 6.1%[66]. - Total current assets as of March 31, 2021, are 2,760,475,116.63 RMB, down from 2,927,663,474.49 RMB at the end of 2020[53]. - Total equity increased from ¥4,192,457,188.45 to ¥4,296,354,443.67, an increase of about 2.5%[62]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 22,886[12]. - The company has not faced any overdue commitments from its actual controllers or shareholders during the reporting period[38]. - The company’s controlling shareholder underwent a change in equity, which requires approval from relevant regulatory bodies before proceeding with stock issuance[32]. Regulatory and Compliance - The company received a regulatory correction order from the China Securities Regulatory Commission on March 3, 2021, due to issues related to fund occupation[35]. - The company is actively addressing regulatory compliance issues as part of its operational strategy[35]. - The company has not reported any non-operating fund occupation by controlling shareholders or related parties during the reporting period[48]. Research and Development - The company reported a significant decrease in research and development expenses by 54.86% to ¥8,165,544.65[24]. - Research and development expenses decreased significantly to ¥2,611,824.06, down 76.3% from ¥11,043,867.32 in the previous period[81]. Business Segments - The blood products business generated total operating revenue of ¥283,471,117.56, a 17.10% increase year-on-year, with net profit rising 43.19%[28]. - Tianan Pharmaceutical reported operating revenue of ¥58,391,867.14, a decrease of 33.73%, with net profit down 36.29%[28]. - New Bai Pharmaceutical's operating revenue was ¥169,703,097.79, a 2.29% increase, but net profit decreased by 36.03%[28]. - Ruda Pharmaceutical achieved sales revenue of ¥158,692,569.99, up 2.79%, with net profit declining by 4.82%[28]. Investment and Fundraising - The total amount of raised funds is 98,925.6 million RMB, with 2,872.83 million RMB invested in the current quarter, representing 2.90% of the total commitment[41]. - The company plans to temporarily use up to 90,000.00 million RMB of idle raised funds to supplement working capital, with a repayment period not exceeding 12 months[44]. - The cumulative amount of pre-invested self-raised funds in the projects reached 11,559,173.17 RMB, with specific allocations for land and design costs[44].